Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 14/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19347016 | 0.93 | TSHR (0.44) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL21427884 | 0.91 | TSHR (0.49) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL19332126 | 0.89 | SLC10A1 (0.45) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL19332176 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL30033987 | 0.89 | SLC10A1 (0.47) | SLC10A1TSHRMAPTSMN1; SMN2NPC1 | |
| SCHEMBL30035645 | 0.89 | SLC10A1 (0.45) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL19347059 | 0.88 | SLC10A1 (0.49) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL22545623 | 0.88 | SLC10A1 (0.49) | SLC10A1MAPTSMN1; SMN2NPC1POLB | |
| SCHEMBL19332348 | 0.88 | SLC10A1 (0.44) | SLC10A1TSHRMAPTSMN1; SMN2LMNA | |
| SCHEMBL21889751 | 0.87 | SLC10A1 (0.45) | SLC10A1TSHRMAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2020072955-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | HAVCR2, HMBS, HDGF | SLC10A1 8/4885TSHR 4386/4885MAPT 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.